Clinical meaning
Metabolic syndrome is a cluster of interconnected cardiometabolic risk factors — central obesity, insulin resistance, dyslipidemia, and hypertension — that synergistically increase the risk of type 2 diabetes (5-fold) and atherosclerotic cardiovascular disease (2-fold). The central pathophysiological driver is insulin resistance in skeletal muscle, liver, and adipose tissue, amplified by visceral adiposity. Visceral adipose tissue is metabolically active, functioning as an endocrine organ that secretes pro-inflammatory adipokines (TNF-alpha, IL-6, resistin) while reducing production of the protective adipokine adiponectin. TNF-alpha impairs insulin signaling by phosphorylating serine residues on insulin receptor substrate-1 (IRS-1), blocking the downstream PI3K/Akt pathway that normally mediates glucose transporter (GLUT-4) translocation to the cell membrane. This insulin resistance in skeletal muscle reduces glucose uptake, while hepatic insulin resistance removes the normal suppression of gluconeogenesis, resulting in hyperglycemia that drives compensatory hyperinsulinemia. In the liver, insulin resistance also increases de novo lipogenesis and VLDL production, producing the characteristic dyslipidemia: elevated triglycerides, reduced HDL cholesterol, and increased small dense LDL particles (the most atherogenic lipoprotein subtype). The hyperinsulinemic state activates the sympathetic nervous system, increases renal sodium reabsorption, and promotes...